Apogee Therapeutics Inc (NASDAQ: APGE) on Tuesday, soared 6.48% from the previous trading day, before settling in for the closing price of $37.06. Within the past 52 weeks, APGE’s price has moved between $31.07 and $72.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 7.87%. With a float of $36.31 million, this company’s outstanding shares have now reached $45.02 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Apogee Therapeutics Inc is 37.94%, while institutional ownership is 80.63%. The most recent insider transaction that took place on Jan 08 ’25, was worth 732,693. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $48.85, taking the stock ownership to the 1,309,487 shares. Before that another transaction happened on Jan 08 ’25, when Company’s Officer proposed sale 15,000 for $48.84, making the entire transaction worth $732,675.
Apogee Therapeutics Inc (APGE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.87% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
Apogee Therapeutics Inc (APGE) is currently performing well based on its current performance indicators. A quick ratio of 16.39 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -4.32 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Apogee Therapeutics Inc (NASDAQ: APGE) saw its 5-day average volume 0.67 million, a positive change from its year-to-date volume of 0.58 million. As of the previous 9 days, the stock’s Stochastic %D was 9.80%. Additionally, its Average True Range was 3.13.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 11.03%, which indicates a significant decrease from 21.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.26% in the past 14 days, which was higher than the 67.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.07, while its 200-day Moving Average is $48.60. Nevertheless, the first resistance level for the watch stands at $40.21 in the near term. At $40.95, the stock is likely to face the second major resistance level. The third major resistance level sits at $42.24. If the price goes on to break the first support level at $38.18, it is likely to go to the next support level at $36.89. Assuming the price breaks the second support level, the third support level stands at $36.15.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
Market capitalization of the company is 2.31 billion based on 45,027K outstanding shares. Right now, sales total 0 K and income totals -83,990 K. The company made 0 K in profit during its latest quarter, and -49,020 K in sales during its previous quarter.
